Clinical Trials
5 trialsNCT00569127 2026-05-26
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05884255 2026-05-19
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06881992 2026-05-18
Tumor HI
Rezolute
Phase 3 Recruiting
NCT07591493 2026-05-15
ADJUPANET
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Not yet recruiting
NCT05918302 2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting